Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2003 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables.
Gadducci A, Guerrieri ME, Cosio S. Gadducci A, et al. Crit Rev Oncol Hematol. 2019 Mar;135:103-114. doi: 10.1016/j.critrevonc.2019.01.006. Epub 2019 Jan 19. Crit Rev Oncol Hematol. 2019. PMID: 30819439 Review.
Palliative chemotherapy is the only treatment option for persistent or recurrent cervical adenocarcinoma not amenable with surgery and radiotherapy. The use of immune checkpoint inhibitors as well as a therapeutic strategy targeting cell surface tyrosine kina …
Palliative chemotherapy is the only treatment option for persistent or recurrent cervical adenocarcinoma not amenable w …
Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease.
Umesaki N, Izumi R, Fushiki H, Hasegawa K, Kono I, Nishida M, Noguchi H, Okuda H, Sugimori H, Takizawa K, Udagawa Y, Yamamoto K, Tanaka T, Noda K. Umesaki N, et al. Gynecol Oncol. 1999 Oct;75(1):142-4. doi: 10.1006/gyno.1999.5556. Gynecol Oncol. 1999. PMID: 10502441 Clinical Trial.
We review the cases of 31 patients with stage IVb or recurrent cervical adenocarcinoma who were treated with combination chemotherapy utilizing mitomycin C, etoposide, and cisplatin (MEP). ...
We review the cases of 31 patients with stage IVb or recurrent cervical adenocarcinoma who were treated with combinatio …
Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog.
Agrawal M, Edgerly M, Fojo T, Kotz H. Agrawal M, et al. Gynecol Oncol. 2003 Jul;90(1):96-9. doi: 10.1016/s0090-8258(03)00146-x. Gynecol Oncol. 2003. PMID: 12821348
OBJECTIVE: The incidence of recurrent cervical adenocarcinoma is rising relative to the squamous subtype. ...This report describes results with BMS-247550, an epothilone B analog that stabilizes microtubules, with activity in previously treated adenocarcinoma …
OBJECTIVE: The incidence of recurrent cervical adenocarcinoma is rising relative to the squamous subtype. ...This repor …
Remission of metastatic cervical adenocarcinoma with weekly paclitaxel.
Ota S, Sugiyama T, Ushijima K, Fujiyoshi K, Komai K, Hirai N, Nishida T, Kamura T. Ota S, et al. Int J Gynecol Cancer. 2001 Mar-Apr;11(2):167-8. doi: 10.1046/j.1525-1438.2001.011002167.x. Int J Gynecol Cancer. 2001. PMID: 11328417
Paclitaxel, 70 mg/m2 by 1-h infusion weekly, was administered to a 59-year-old patient with cervical adenocarcinoma showing lung metastasis. She showed partial clinical response after seven cycles, and at the completion of 20 cycles she showed complete response, which was …
Paclitaxel, 70 mg/m2 by 1-h infusion weekly, was administered to a 59-year-old patient with cervical adenocarcinoma showing lung metastasis. …